FREE Case Review (866) 588-0600

Study Highlights Risks of Combining Onglyza with Other Diabetes Drugs

Combining DPP-4 inhibitor diabetes medicines with “sulphonylureas” may increase the risk of hypoglycemia (low blood sugar), a new study has found.

A new study has found that combining DPP-4 inhibitors like Onglyza (generic: saxagliptin) with “sulphonylureas” may increase the risk of hypoglycemia (low blood sugar), a potentially life-threatening condition.

Free Confidential Lawsuit Evaluation: If you or a loved one was injured by Onglyza side effects, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.

What’s the Problem?

June 23, 2016 – According to the study, which was published May 3 in the British Medical Journal (BMJ), hypoglycemia has emerged as a leading complication of diabetes in patients who are 60 years or older, and who have a long history of the disease. Low blood sugar is the 2nd leading cause of hospitalization for type 2 diabetics, which accounts for 20-25% of hospital admissions for adverse drugs reactions. The condition has also been linked to an increased risk for falls and fractures, according to the study.

DPP-4 inhibitors are indicated as a second line treatment for type 2 diabetes patients who aren’t able to control their blood sugar levels with one medication alone. The drugs stimulate the pancreas to produce more insulin after a meal, so the body can better metabolize glucose and keep blood sugar levels steady. In addition to Onglyza, other DPP-4 inhibitors include Januvia (sitagliptin), Janumet (sitagliptin and metformin) and Nesina (alogliptin).

For the study, researchers looked at data from 10 studies which included 6,546 test subjects. A total of 4,020 patients were taking DPP-4 inhibitors along with sulphonylureas, and 2,526 had been given a placebo plus sulphonylureas.

The DPP-4 inhibitor plus sulphonylurea group had a 50% increased risk for hypoglycemia compared to the sulphonylurea plus placebo, according to the results. The study’s authors warned that prescribing doctors should “respect recommendations for a decrease in sulphonylureas dose when initiating DPP-4 inhibitors.”

The study follows an April 2016 FDA Drug Safety Communication stating that the labeling of DPP-4 inhibitors would be updated to include a heart failure warning.

Do I Have an Onglyza Lawsuit?

The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Onglyza lawsuits. We are handling individual litigation nationwide and currently accepting new cancer and heart failure cases in all 50 states.

Free Confidential Case Evaluation: Again, if you were diagnosed with cancer or heart failure after taking Onglyza, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.
Awards & recognition